Search Result

Results for "

item/HY-16562

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Antibiotic (1) Apoptosis (4) ATM/ATR (1) ATP Synthase (1) Autophagy (8) Bacterial (1) BCRP (2) Biochemical Assay Reagents (1) Cannabinoid Receptor (1) Carboxylesterase (CES) (1) Cholinesterase (ChE) (1) Claudin (1) Drug Intermediate (2) Drug Metabolite (3) Drug-Linker Conjugates for ADC (2) Endogenous Metabolite (3) Estrogen Receptor/ERR (1) GLUT (1) HDAC (1) Integrin (1) Isotope-Labeled Compounds (6) Leukotriene Receptor (1) mTOR (1) Natriuretic Peptide Receptor (NPR) (1) PARP (1) Peptide-Drug Conjugates (PDCs) (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) Topoisomerase (12) Transthyretin (TTR) (1) α-synuclein (1) β-glucuronidase (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Metabolic Disease (9) Neurological Disease (3)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: HyT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16562

Irinotecan Maximum Cited Publications 75 Publications Verification (+)-Irinotecan; CPT-11; VAL-413free base	Topoisomerase Autophagy	Neurological Disease Cancer
Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .

HY-16562A

Irinotecan hydrochloride 70+ Cited Publications (+)-Irinotecan HYdrochloride; CPT-11 HYdrochloride; VAL-413	Topoisomerase Autophagy	Cancer
Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-126373

SN-38 glucuronide SN-38G	Drug Metabolite	Cancer
SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-113283

Homogentisic acid	Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin	Neurological Disease Metabolic Disease Cancer
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ_1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .

HY-12757

YHO-13177 2 Publications Verification	BCRP	Cancer
YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC₅₀ value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .

HY-W012985

Methyl pyruvate	ATP Synthase Apoptosis	Metabolic Disease Cancer
Methyl pyruvate is a methyl ester derivative of pyruvic acid. Methyl pyruvate induces insulin release and membrane depolarization. Methyl pyruvate rescues proteasome damage and nuclear localization of TdP-43 caused by overexpression of σ1RE102Q by enhancing ATP synthesis. Methyl pyruvate selectively protects normal lung fibroblasts from cell death induced by Irinotecan (HY-16562). Methyl pyruvate promotes apoptosis and necrosis in cancer cells and downregulates angiogenesis and cell cycle pathways. Methyl pyruvate is an effective substrate for dihydrodihydrogen dehydrogenase.

HY-173243A

Val-Ala-PAB-SN38 TFA	Drug-Linker Conjugates for ADC	Cancer
Val-Ala-PAB-SN38 TFA is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562) .

HY-16562S1

Irinotecan-d10 hydrochloride	Isotope-Labeled Compounds Topoisomerase Autophagy	Cancer
Irinotecan-d₁₀ (hydrochloride) is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .

HY-W105318

Pentabromophenol PBP	TGF-beta/Smad Apoptosis	Cancer
Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .

HY-145525

Linoleoyl-L-carnitine chloride CAR 18:2; C18:2 Carnitine; L-Carnitine linoleoyl ester	Endogenous Metabolite	Others
Linoleoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Hepatic levels of linoleoyl-L-carnitine are increased following high-dose (200 mg/kg) administration of Isoniazid (Item No. 20378) in mice.

HY-137555

11-dehydro-2,3-dinor Thromboxane B2 11-deHYdro-2,3-dinor TXB2	Endogenous Metabolite	Metabolic Disease
11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.

HY-P10783

BGC0222	Peptide-Drug Conjugates (PDCs) Integrin	Cancer
BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to α_Vβ₃ with IC₅₀ values of 4.25 μM (α_Vβ₃) and 58.7 μM (α_Vβ₅). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .

HY-173243

Val-Ala-PAB-SN38	Drug-Linker Conjugates for ADC	Cancer
Val-Ala-PAB-SN38 is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562) .

HY-17648

MBL-II-141	BCRP	Cancer
MBL-II-141 is potent ABCG2 inhibitor with an IC₅₀ of 0.11 μM. MBL-II-141 inhibits the transport function of ABCG2 in a non-competitive manner, preventing ABCG2 from pumping substrates (such as Irinotecan (HY-16562)) out of the cells, thereby increasing the accumulation of drugs within the cells. MBL-II-141 has no effect on ABCB1 (P-gp) and ABCC1 (MRP1) and has extremely low cytotoxicity (IG₅₀ > 100 μM). MBL-II-141 can be used for the study of multidrug resistance (MDR) cancers .

HY-W114419

Bisphenol C	Estrogen Receptor/ERR mTOR	Cardiovascular Disease Metabolic Disease
Bisphenol C is an estrogen receptor-α (ERα) agonist and an ERβ antagonist, with IC₅₀ values of 2.65 nM for ERα and 1.94 nM for ERβ. Bisphenol C is a material of manufacturing polyester polymers like polycarbonate, is widely used in daily items like water bottles, food packaging, textile and so on .

HY-Z11281

Irinotecan impurity 52	Drug Intermediate	Others
Irinotecan impurity 52 is an impurity of Irinotecan (HY-16562).

HY-164271

10-Boc-SN-38	Topoisomerase	Cancer
10-Boc-SN-38 is a tert-butyloxycarbonyl (Boc)-protected form of SN-38 (HY-13704). SN-38 is the active metabolite of Irinotecan (HY-16562) .

HY-155034

Antitumor agent-102	Topoisomerase GLUT	Cancer
Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .

HY-116661

Cannabigerovarin CBGV	Cannabinoid Receptor	Metabolic Disease
Cannabigerovarin (CRM) (Item No. 29117) is a certified reference material categorized as a phytocannabinoid.1 This product is intended for research and forensic applications.

HY-16562S

Irinotecan-d10 (+)-Irinotecan-d10; CPT-11-d10; VAL-413-d10free base	Topoisomerase Autophagy	Cancer
Irinotecan-d₁₀ is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .

HY-16562R

Irinotecan (Standard) (+)-Irinotecan (Standard); CPT-11 (Standard); VAL-413free base (Standard)	Reference Standards Topoisomerase Autophagy	Cancer
Irinotecan (Standard) is the analytical standard of Irinotecan. This product is intended for research and analytical applications. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .

HY-16562AR

Irinotecan hydrochloride (Standard) (+)-Irinotecan HYdrochloride (Standard); CPT-11 HYdrochloride (Standard); VAL-413 (Standard)	Reference Standards Topoisomerase Autophagy	Cancer
Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-16562AS

Irinotecan-d5 hydrochloride (+)-Irinotecan-d5 (HYdrochloride; CPT-11-d5 HYdrochloride; VAL-413-d5	Autophagy Topoisomerase Isotope-Labeled Compounds	Cancer
Irinotecan-d₅ hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .

HY-W653919

SN-38 glucuronide-d3	Isotope-Labeled Compounds Drug Metabolite	Cancer
SN-38 glucuronide-d₃ is deuterium labeled SN-38 glucuronide. SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-141436R

Sucrosofate potassium (Standard) Sucrose octasulfate potassium (Standard)	Biochemical Assay Reagents Reference Standards	Cancer
Sucrosofate (potassium) (Standard) is the analytical standard of Sucrosofate (potassium). This product is intended for research and analytical applications. Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .

HY-132561S

RPR121056-d3 APC-d₃	Isotope-Labeled Compounds Topoisomerase Cholinesterase (ChE)	Cancer
RPR121056-d3 is the deuterium labeled RPR121056. RPR121056 is a metabolite of Irinotecan (HY-16562), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the study of colorectal cancer. Irinotecan also directly inhibits AChE .

HY-149291

ATM Inhibitor-7	ATM/ATR Apoptosis	Cancer
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC₅₀ value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .

HY-119992

CEP-6800	PARP	Cancer
CEP-6800 is an inhibitor of PARP-1 with chemopotentiating ability. CEP-6800 attenuates irinotecan (HY-16562)- and Temozolomide (HY-17364)-induced poly(ADP-ribose) accumulation in LoVo as well as HT29 xenografts. CEP-6800 can suppress Calu-6 tumor growth. CEP-6800 can be studied in anti-cancer research .

HY-130340

Teicoplanin A3-1 Teichomycin A3 factor 1; Antibiotic L 17054	Antibiotic	Infection
Teicoplanin A3-1 is a degradation product of teicoplanins A2-1 to 5 (Item Nos. 20187, 20188, 20189, 20192). Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro.

HY-173267

CES2A-IN-2	Carboxylesterase (CES)	Metabolic Disease Cancer
CES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent CES2A inhibitor with an IC₅₀ of 0.04 nM for human CES2A. CES2A-IN-2 covalently binds to CES2A by specifically targeting the catalytic serine residue (Ser-228). CES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan (HY-16562) in tumor-bearing mice .

HY-159966

Top/HDAC-IN-3	Topoisomerase HDAC Reactive Oxygen Species (ROS) Apoptosis	Cancer
Top/HDAC-IN-3 (Compound 31) is an orally active dual inhibitor of Topoisomerase and HDAC. Top/HDAC-IN-3 increases reactive oxygen species (ROS) levels, leading to DNA damage, thereby inhibiting cancer cell colony formation and migration, inducing cancer cell Apoptosis, and causing cell cycle arrest. In the NSCLC model, Top/HDAC-IN-3 exhibited significant antitumor effects, with a tumor growth inhibition (TGI) of 77.5% at 100 mg/kg, surpassing the efficacy of the HDAC inhibitor SAHA (HY-10221) and the combination of SAHA (HY-10221) with the topoisomerase inhibitor Irinotecan (HY-16562) .

HY-RS16562

Sp1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Sp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sp1 Mouse Pre-designed siRNA Set A Sp1 Mouse Pre-designed siRNA Set A

HY-173397

β-Glucuronidase-IN-3	β-glucuronidase Bacterial	Metabolic Disease
β-Glucuronidase-IN-3 (Compound 49) is a covalent allosteric β-glucuronidase inhibitor. β-Glucuronidase-IN-3 has potent inhibitory activity against Escherichia coli β-glucuronidase (EcGUS) (IC₅₀: 12.9 nM). β-Glucuronidase-IN-3 exerts its inhibitory effect by reversibly covalently modifying the cysteine residues (Cys28, Cys443, and Cys197) of EcGUS. β-Glucuronidase-IN-3 can be used in the study of intestinal microbiota-related diseases, especially to alleviate the toxic side effects of Irinotecan (HY-16562) and nonsteroidal anti-inflammatory drugs (NSAIDs) .

HY-124200

AL 8810 isopropyl ester	Prostaglandin Receptor	Endocrinology
AL 8810 (Item No. 16735) is an 11β-fluoro analog of prostaglandin F2α which acts as a potent and selective antagonist at the FP receptor. AL 8810 isopropyl ester is a lipid soluble, esterified prodrug form of AL 8810 analogous to the commonly used therapeutic intraocular prostaglandin compounds such as Latanoprost (HY-B0577) and Travoprost (HY-B0584).

HY-129303

AP219	Endogenous Metabolite	Metabolic Disease
AP39 (Item No. 17100) is a compound used to increase the levels of hydrogen sulfide (H2S) within mitochondria. It consists of a mitochondria-targeting motif (triphenylphosphonium) coupled to an H2S-donating moiety (dithiolethione) by an aliphatic linker. AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.

HY-134123

Lipoxin B4 methyl ester LXB4 metHYl ester	Drug Intermediate Leukotriene Receptor	Metabolic Disease
Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC₅₀ value of 0.3 nM.

HY-16562S2

Irinotecan-13C6 (+)-Irinotecan-¹³C₆; CPT-11-¹³C₆; VAL-413-¹³C₆ free base	Isotope-Labeled Compounds Autophagy Topoisomerase	Neurological Disease Cancer
Irinotecan- ¹³C₆ ((+)-Irinotecan- ¹³C₆) is the ¹³C-labeled Irinotecan (HY-16562). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .

HY-126373S

SN-38 glucuronide-d5 SN-38G-d₅	Isotope-Labeled Compounds Drug Metabolite	Cancer
SN-38 glucuronide-d₅ (SN-38G-d₅) is the deuterium labeled SN-38 glucuronide (HY-126373). SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer.

Cat. No.	Product Name

HY-L0096V

Vitas-M Screening Compounds Library	1,400,000 compounds
Vitas-M Screening Compounds Library (stock) contains about 1,400,000 chemical substances. They are synthetic small molecule organic compounds for biological screening and lead optimization. Select any number of items as a "cherry pick".

HY-L055

Medicine Food Homology Compound Library	1,801 compounds
Medicine Food Homology (MFH) means that some food themselves are medicines and there is no absolute boundary between them. MFH theory combines the function of food and medicine together scientifically and MFH materials can be used both for food and medicine. Besides nutritional value, MFH materials also have the functions in the prevention and treatment of disease and many other healthcare effects. Food as medicines has many benefits because of their safety while taking drugs will bring inevitable side effect to people. In order to ensure the safe use of functional food, National Health Commission of People's Republic of China made specific provisions on MFH items. More than 100 kinds of widely used MFH materials have been released. Based on MFH items released by National Health Commission, PRC, MCE carefully designs a unique collection of 1,801 Medicine Food Homology Compounds with high safety that can be used for high throughput and high content screening for drug discovery.

Medicine Food Homology Compound Library

1,801 compounds

Medicine Food Homology (MFH) means that some food themselves are medicines and there is no absolute boundary between them. MFH theory combines the function of food and medicine together scientifically and MFH materials can be used both for food and medicine. Besides nutritional value, MFH materials also have the functions in the prevention and treatment of disease and many other healthcare effects. Food as medicines has many benefits because of their safety while taking drugs will bring inevitable side effect to people. In order to ensure the safe use of functional food, National Health Commission of People's Republic of China made specific provisions on MFH items. More than 100 kinds of widely used MFH materials have been released.

Based on MFH items released by National Health Commission, PRC, MCE carefully designs a unique collection of 1,801 Medicine Food Homology Compounds with high safety that can be used for high throughput and high content screening for drug discovery.

HY-L0088V

Life Chemicals 50K Diversity Library	50,240 compounds
Life Chemicals presents a number of exclusive Pre-Plated Diversity Sets composed of 50,240 novel compounds with optimal physicochemical properties selected from Life Chemicals collection of newly synthesized items by dissimilarity search with an average Tanimoto threshold of 82%. These Diverse Screening Sets are ideal starting points for customers looking for a wide range of dissimilarity to screen against a number of targets from different classes or where little information is available on targeted protein structure.

Life Chemicals 50K Diversity Library

50,240 compounds

Life Chemicals presents a number of exclusive Pre-Plated Diversity Sets composed of 50,240 novel compounds with optimal physicochemical properties selected from Life Chemicals collection of newly synthesized items by dissimilarity search with an average Tanimoto threshold of 82%. These Diverse Screening Sets are ideal starting points for customers looking for a wide range of dissimilarity to screen against a number of targets from different classes or where little information is available on targeted protein structure.

Cat. No.	Product Name	Target	Research Area